Navigating cancer therapy: Harnessing the power of peptide-drug conjugates as precision delivery vehicles.
Quick Facts
What This Study Found
Peptide-drug conjugates offer targeted cancer delivery by linking tumor-homing peptides to cytotoxic drugs via specialized linkers, reducing off-target toxicity compared to chemotherapy.
Key Numbers
PDC components: targeting ligand + cytotoxic payload + linker; several in clinical trials; challenges: plasma stability, elimination, oral bioavailability
How They Did This
Narrative review of PDC design, delivery mechanisms, clinical applications, and limitations.
Why This Research Matters
Traditional chemotherapy damages healthy cells alongside cancer cells. PDCs aim to deliver the drug directly to tumors, potentially improving outcomes while reducing side effects.
What This Study Doesn't Tell Us
Narrative format without systematic search. Many PDCs discussed are still experimental. Clinical data are limited for most candidates.
Trust & Context
- Original Title:
- Navigating cancer therapy: Harnessing the power of peptide-drug conjugates as precision delivery vehicles.
- Published In:
- European journal of medicinal chemistry, 283, 117131 (2025)
- Authors:
- Sagar, Bulbul, Gupta, Sarthak, Verma, Sarvesh Kumar, Reddy, Y Veera Manohara, Shukla, Shefali
- Database ID:
- RPEP-13361
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13361APA
Sagar, Bulbul; Gupta, Sarthak; Verma, Sarvesh Kumar; Reddy, Y Veera Manohara; Shukla, Shefali. (2025). Navigating cancer therapy: Harnessing the power of peptide-drug conjugates as precision delivery vehicles.. European journal of medicinal chemistry, 283, 117131. https://doi.org/10.1016/j.ejmech.2024.117131
MLA
Sagar, Bulbul, et al. "Navigating cancer therapy: Harnessing the power of peptide-drug conjugates as precision delivery vehicles.." European journal of medicinal chemistry, 2025. https://doi.org/10.1016/j.ejmech.2024.117131
RethinkPeptides
RethinkPeptides Research Database. "Navigating cancer therapy: Harnessing the power of peptide-d..." RPEP-13361. Retrieved from https://rethinkpeptides.com/research/sagar-2025-navigating-cancer-therapy-harnessing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.